This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com highlights: HollyFrontier, Amedisys, MGM Growth Properties, Louisiana-Pacific and Houlihan Lokey
by Zacks Equity Research
Zacks.com highlights: HollyFrontier, Amedisys, MGM Growth Properties, Louisiana-Pacific and Houlihan Lokey
Bet on These 5 Low Leverage Stocks for Safe Returns
by Zacks Equity Research
As we are off to a strong start in the Q2 earnings season, blindly pursuing high earnings yielding stocks might drain all your money before you know, if the stock bears a high debt-to-equity ratio.
Weekly Jobless Claims Plunge to 48-Year Low: 5 Top Picks
by Nalak Das
Job additions continued to be substantial in June, indicating that hiring remains robust even as the economy nears full employment.
4 Reasons to Add Anadarko Petroleum (APC) to Your Portfolio
by Zacks Equity Research
Anadarko Petroleum (APC) seems a lucrative choice, promising better returns for investors on the back of four factors.
The Zacks Analyst Blog Highlights: Korn/Ferry International, Avis Budget Group, Regal Beloit, Amedisys and Jacobs Engineering Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Korn/Ferry International, Avis Budget Group, Regal Beloit, Amedisys and Jacobs Engineering Group
Outpatient & Home Healthcare Stock Outlook: Prospects Bright
by Zacks Equity Research
The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.
Profit From Strong Job Additions With These 5 Top-Ranked Picks
by Swarup Gupta
June's jobs report indicates that corporations are successfully filling up open positions even as the pool of skilled workers continues to shrink.
Buy These 5 Low Leverage Stocks on Chances of Rate Hike
by Zacks Equity Research
Prudent investors try to avoid companies with large debt loads since they are more vulnerable during economic downturns.
Brush Off Volatility Concerns With These 5 Low-Beta Stocks
by Zacks Equity Research
We create a strategy that singles out less-risky stocks which can generate impressive returns only when certain parameters are considered.
5 Knockout Stocks to Play the World Cup Fever Pitch
by Ritujay Ghosh
Much like any tournament can't be won without putting up a strong fight, markets too go through ups and downs. Amid all the odds, stock winners leave a mark with their performance.
Is Amedisys (AMED) a Great Growth Stock?
by Zacks Equity Research
Amedisys (AMED) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth
by Zacks Equity Research
QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.
Buy These 5 Low Leverage Stocks Amid Rising Trade Tensions
by Zacks Equity Research
For a safe investment strategy, understanding the amount of financial leverage that a company bears is crucial. This is because financial leverage multiplies the underlying business risk.
Hologic's New Panther Fusion System Gets Health Canada Nod
by Zacks Equity Research
Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.
Medtronic's Expanded IN.PACT Admiral FDA Nod to Aid APV Arm
by Zacks Equity Research
Medtronic's (MDT) receipt of FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.
Envision Healthcare's (EVHC) Ratings on Review for Downgrade
by Zacks Equity Research
Moody's Investor Service puts Envision Healthcare's (EVHC) ratings and outlook on review for downgrade.
Zacks.com highlights: G-III Apparel Group, Momo, Weight Watchers International, Amedisys and Urban Outfitters
by Zacks Equity Research
Zacks.com highlights: G-III Apparel Group, Momo, Weight Watchers International, Amedisys and Urban Outfitters
CVS Health's PBM Selling Season Remains Solid, Retail Grows
by Zacks Equity Research
CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.
5 Stocks to Snap Up on Explosive Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
Top Ranked Momentum Stocks to Buy for June 11th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 11th:
Top Ranked Momentum Stocks to Buy for June 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 8th:
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.
ResMed Reports Positive Results for Bilevel PAP Device Study
by Zacks Equity Research
Positive results from the Bilevel Rescue study are expected to boost the uptake of ResMed's (RMD) bilevel devices.
Why Amedisys (AMED) Stock Might be a Great Pick
by Zacks Equity Research
Amedisys (AMED) is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.